• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Ask the Editor: Which Antipsychotic Is Best When Patients Complain of Akathisia?

Ask the Editor: Which Antipsychotic Is Best When Patients Complain of Akathisia?

November 1, 2018
Chris Aiken, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Each month, Editor-in-Chief Chris Aiken, MD, gives advice on a different practice challenge.

If you have a question you’d like Dr. Aiken to answer, please send an email to AskTheEditor@thecarlatreport.com.

Dr. Aiken won’t be able to answer all questions received, but he will pick one each month that is of general interest.

Which Antipsychotic Is Best When Patients Complain of Akathisia?
Akathisia is a sensation of inner restlessness so unpleasant that it independently elevates the risk of suicide. Among atypicals, quetiapine (Seroquel) has the lowest risk of akathisia, but that doesn’t mean it’s easy to take. Its other adverse effects, like sedation, weight gain, and hypotension, lead to more premature discontinuation and emergency room visits than with other antipsychotics (Hampton LM et al, JAMA Psych 2014;71:1006–1014; Zhou X et al, Int J Neuropsychopharmacol 2015;18:pyv060). So, it’s helpful to know the runner-ups. Rates are also low for iloperidone, brexpiprazole, clozapine, and possibly ziprasidone* and olanzapine*.

Newer is not always better. Cariprazine and lurasidone are among the worst offenders, but other new medications have lower rates of akathisia than the antipsychotics they were derived from (iloperidone and paliperidone < risperidone; brexpiprazole < aripiprazole). The highest rates are seen with high-potency conventional antipsychotics like haloperidol and fluphenazine.

The table lumps atypicals by their number needed to harm (NNH) for akathisia in schizophrenia. In mood disorders, the rates are higher but the pattern is similar. However, akathisia is difficult to measure reliably, and there are few head-to-head comparisons.

Akathisia is dose-dependent, so starting low and titrating slowly can help. Antidotes are numerous. Beta-blockers are first-line (propranolol 30–90 mg/day, betaxolol 10–20 mg/day). Treatments for restless leg syndrome can be helpful (rotigotine 2–8 mg/day, clonazepam 0.5–2.5 mg/day, ­gabapentin 300–1200 mg/day, ­amantadine ­100–200 mg bid), and small studies support the use of 5-HT2A ­antagonists (­trazodone 50–100 mg/night, ­mirtazapine ≤ 15 mg/night, ­cyproheptadine 16 mg/night) and vitamin B6 (600 mg bid).

*Studies are inconsistent, reporting both high and low rates.

Table: Risk of Akathisia With Atypical Antipsychotics


Table: Risk of Akathisia With Atypical Antipsychotics


(Click here to view as a full-size PDF.)

General Psychiatry
KEYWORDS antipsychotics
    Aiken eic 150x150
    Chris Aiken, MD

    The Antipsychotic-Stimulant Combo

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Drug Metabolism, TCPR, November/December 2018
    New Approvals for TMS
    Is Clozapine the Next Step After a Single Failed Antipsychotic Trial?
    Does TMS Really Work in Depression?
    Probiotics for Bipolar Disorder
    Ask the Editor: Which Antipsychotic Is Best When Patients Complain of Akathisia?
    Effects of Drug Interactions
    Harnessing Beneficial Drug Interactions
    New Stimulants: From Remixed Amphetamines to Bedtime Ritalin
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.